BHV
Biohaven
Stock
Stock
ISIN: VGG1110E1079
Ticker: BHVN
VGG1110E1079
BHVN
Price
Price
CHART BY
Frequently asked questions
What is Biohaven's market capitalization?
The market capitalization of Biohaven is $1.76B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Biohaven?
Biohaven's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$7.658. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Biohaven's stock?
Currently, 18 analysts cover Biohaven's stock, with a consensus target price of $44.63. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Biohaven?
Biohaven's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$797.28M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Biohaven?
Biohaven has a free cash flow of -$646.43M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Biohaven have, and what sector and industry does it belong to?
Biohaven employs approximately 256 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Biohaven's shares?
The free float of Biohaven is 92.38M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.76B
- EPS (TTM)
- -$7.658
- Free Float
- 92.38M
- EBITDA (TTM)
- -$797.28M
- Free Cashflow (TTM)
- -$646.43M
Pricing
- 52W span
- $12.80$54.95
Analyst Ratings
The price target is $44.63 and the stock is covered by 18 analysts.
Buy
17
Hold
1
Sell
0
Information
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.
- Employees
- 256
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- VGG1110E1079
- Primary Ticker
- BHVN
Fundamentals & EOD data from FactSet